Linked Life Data

17502230

Source:http://linkedlifedata.com/resource/pubmed/id/17502230

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-5-15
pubmed:abstractText
Antiretroviral management of treatment-naive patients begins with the decision of when to start treatment. Current treatment guidelines suggest starting therapy in anyone with AIDS, HIV-related symptoms, or a CD4 cell count less than 200/mm3 regardless of symptoms. Starting treatment in asymptomatic patients with CD4 of more than 200 requires consideration of a number of pros and cons, and individualization is the key. Recommended first-line antiretroviral regimens consist of two nucleoside reverse transcriptase inhibitors together with either a nonnucleoside reverse transcriptase inhibitor or a protease inhibitor (with or without ritonavir boosting). The goal of antiretroviral therapy is maximally to suppress viremia, enhance or improve immune function, and prevent clinical progression.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0891-5520
pubmed:author
pubmed:issnType
Print
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
71-84, viii
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Antiretroviral management of treatment-naive patients.
pubmed:affiliation
Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA. rgulick@med.cornell.edu
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural